BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32097841)

  • 21. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
    Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
    J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2015 Aug; 23(15):4871-4883. PubMed ID: 26071372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
    Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
    Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
    Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
    Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
    Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
    J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
    Dai J; Yang L; Addison G
    Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.
    Su W; Chen Z; Liu M; He R; Liu C; Li R; Gao M; Zheng M; Tu Z; Zhang Z; Xu T
    Bioorg Med Chem Lett; 2022 May; 64():128680. PubMed ID: 35306167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
    Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
    J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
    Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
    ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
    Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
    Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective inhibitors of the Janus kinase Jak3--Are they effective?
    Thoma G; Drückes P; Zerwes HG
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
    Ge Y; Wang C; Song S; Huang J; Liu Z; Li Y; Meng Q; Zhang J; Yao J; Liu K; Ma X; Sun X
    Eur J Med Chem; 2018 Jan; 143():1847-1857. PubMed ID: 29146136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
    Casimiro-Garcia A; Trujillo JI; Vajdos F; Juba B; Banker ME; Aulabaugh A; Balbo P; Bauman J; Chrencik J; Coe JW; Czerwinski R; Dowty M; Knafels JD; Kwon S; Leung L; Liang S; Robinson RP; Telliez JB; Unwalla R; Yang X; Thorarensen A
    J Med Chem; 2018 Dec; 61(23):10665-10699. PubMed ID: 30423248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.
    Pei H; He L; Shao M; Yang Z; Ran Y; Li D; Zhou Y; Tang M; Wang T; Gong Y; Chen X; Yang S; Xiang M; Chen L
    Sci Rep; 2018 Mar; 8(1):5273. PubMed ID: 29588471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
    Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
    Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
    Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
    ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.
    Gehringer M; Forster M; Pfaffenrot E; Bauer SM; Laufer SA
    ChemMedChem; 2014 Nov; 9(11):2516-27. PubMed ID: 25139757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of highly potent, selective, covalent inhibitors of JAK3.
    Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.
    Chi F; Chen L; Wang C; Li L; Sun X; Xu Y; Ma T; Liu K; Ma X; Shu X
    Bioorg Chem; 2020 Jan; 95():103542. PubMed ID: 31918398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.